When was ArpIda founded?

ArpIda was founded in 1997 and raised its 1st funding round 3 years after it was founded.

Where is ArpIda located?

ArpIda is headquartered in Reinach, Switzerland.

How many employees does ArpIda have?

As of Jul 31, 2026, the latest employee count at ArpIda is 30.

Is ArpIda a funded company?

ArpIda is a funded company, having raised a total of $90.4M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 08, 2000.

When was the latest funding round of ArpIda?

ArpIda's latest funding was a $***** Series C round on Oct 15, 2004, with participation from 7 investors. Its primary sector is Infectious Diseases. In Switzerland, the Infectious Diseases sector has seen $19.3M in funding in 2026 to date.

Where does ArpIda rank among its competitors?

ArpIda ranks 75th amongst 212 active competitors, of which 77 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Vedanta Biosciences, which secured $60M in Aug, 2026.

Who are the top competitors of ArpIda?

ArpIda's top competitors include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Among them, Vedanta Biosciences secured the most recent funding round in August, 2026.

ArpIda - 2026 Company Profile, Team, Funding & Competitors

ArpIda is an acquired company based in Reinach (Switzerland), founded in 1997. It operates as a Developer of drugs for the treatment of microbial resistance. ArpIda has raised $90.4M in funding from investors like LD Fonde, Carlsberg Group and O-Bank. The company has 212 active competitors, including 77 funded and 40 that have exited. Its top competitors include companies like Spero Therapeutics, Locus Biosciences and LimmaTech Biologics.

Company Details

Developer of drugs for the treatment of microbial resistance. The company's product candidate is intravenous iclaprim, an antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

Key Metrics

Founded Year

1997

Location

Reinach, Switzerland

Stage

Acquired

Total Funding

$90.4M in 3 rounds

Latest Funding Round

Series C, Oct 15, 2004, $*****

Investors

LD Fonde & 13 more

Ranked

75^th among 212 active competitors

Employee Count

30 as on Jul 31, 2026

Similar Companies

Spero Therapeutics & 264 more

Exit Details

Acquired by Evolva (Sep 10, 2009)

View ArpIda's full profile

ArpIda got acquired by Evolva on Sep 10, 2009.

Click here to take a look at ArpIda's acquisition in detail

ArpIda has raised a total funding of $90.4M over 3 rounds. Its first funding round was on Nov 08, 2000. Its latest funding round was a Series C round on Oct 15, 2004 for $*****. 7 investors participated in its latest round. ArpIda has 14 institutional investors.

Here is the list of recent funding rounds of ArpIda:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 15, 2004	6206370	Series C	4709653	1232936	1056111	8122662
May 11, 2004	2419923	Series C	2796570	1708744	5159717	8428671
Nov 08, 2000	3516356	Series A	2875805	7874877	8726682	8868014

Access funding benchmarks and valuations. Sign up today!

View details of ArpIda's funding rounds and investors

ArpIda's employee count trend

ArpIda has 30 employees as of Jul 26. Here is ArpIda's employee count trend over the years:

Uncover ArpIda's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ArpIda include Spero Therapeutics, Locus Biosciences and LimmaTech Biologics. Here is the list of Top 10 competitors of ArpIda, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Spero Therapeutics 2013, Cambridge (United States), Public	Developer of therapeutics for drug-resistant bacterial infections	$115M	Atlas Venture, Partners Health Care Innovation ... & 16 others	69/100
2nd	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
3rd	LimmaTech Biologics 2015, Schlieren (Switzerland), Acquired	Developing bioconjugate vaccines using glycoengineering and protein glycosylation techniques	$40M	REPAIR Impact Fund, Tenmile & 4 others	63/100
4th	Paratek Pharma 1996, Boston (United States), Acquired	Developer of therapeutics for antimicrobial resistant infections	$96.5M	Phase4 Partners, Athyrium Capital Management ... & 25 others	61/100
5th	Melinta Therapeutics 2000, Morristown (United States), Acquired	Developer of therapeutics for antibiotic-resistant infections	$186M	Warburg Pincus, SR One & 16 others	61/100
6th	Everest Medicines 2017, New York City (United States), Public	Developer of drugs for the treatment of cancer	$313M	Hillhouse, RA Capital Management & 12 others	61/100
7th	Bioversys 2008, Basel (Switzerland), Public	Developer of therapeutics for Antimicrobial Resistance	$62.5M	AMR Action Fund, Wellcome Trust & 10 others	61/100
8th	MicuRx Pharmaceuticals 2007, Foster City (United States), Series E	Develops antibiotics against multidrug-resistant (MDR) superbug infections	$272M	BioVeda China Fund, Legend Capital & 9 others	60/100
9th	Vedanta Biosciences 2010, Cambridge (United States), Series E	Developer of therapeutics to treat infectious diseases	$410M	Invesco, Seventure Partners & 40 others	59/100
10th	smartbax 2021, Munich (Germany), Seed	Developer of multi-targeted antibacterial compounds	$7.51M	Anobis Asset, Bayern Kapital & 4 others	59/100
75th	ArpIda 1997, Reinach (Switzerland), Acquired	Developer of drugs for the treatment of microbial resistance	$90.4M	Omega Funds, Novo Holdings & 12 others	39/100